|
Factors Affecting Toxicity, Response and Time to Progression (TTP) in Relapsed Patients with Indolent B-NHL and Mantle Cell Lymphoma (MCL) Treated with Rituximab. |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bellicum Pharmaceuticals; Dendreon; Johnson & Johnson; Medivation; Oncogenex; Progenics (Inst); Sanofi; Tokai Pharmaceuticals |
Research Funding - Bayer (Inst); Dendreon (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bellicum Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Progenics; Sanofi; Tokai Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Janssen-Cilag; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; GlaxoSmithKline; Janssen-Cilag; Pfizer |
|
|
Honoraria - Bayer; Janssen Oncology; Pfizer; Sanofi |
Consulting or Advisory Role - Bayer; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Bayer; Janssen Oncology; Pfizer; Sanofi |
|
Camilla Thellenberg Karlsson |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; MSD; Roche; Sanofi |
|
|
Consulting or Advisory Role - Bayer; Ipsen; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Employment - Bayer; Merck |
Stock and Other Ownership Interests - Amgen; Bayer; Merck |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
No Relationships to Disclose |